Edition:
United States

Spark Therapeutics Inc (ONCE.O)

ONCE.O on Nasdaq

100.78USD
23 Aug 2019
Change (% chg)

$-0.47 (-0.46%)
Prev Close
$101.25
Open
$101.49
Day's High
$101.88
Day's Low
$100.57
Volume
416,989
Avg. Vol
486,244
52-wk High
$114.20
52-wk Low
$34.53

About

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a... (more)

Overall

Beta: --
Market Cap(Mil.): $3,132.52
Shares Outstanding(Mil.): 35.82
Dividend: --
Yield (%): --

Financials

  ONCE.O Industry Sector
P/E (TTM): -- 69.38 32.67
EPS (TTM): -6.38 -- --
ROI: -61.15 8.95 14.48
ROE: -63.88 10.09 15.78

Roche, Spark push back takeover deadline in $4.3 billion deal

ZURICH Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker's $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains "fully committed" to a deal it sees closing this year.

Jul 08 2019

BRIEF-Roche And Spark Therapeutics Receive Information Request From Federal Trade Commission

* ROCHE AND SPARK THERAPEUTICS, INC. RECEIVE REQUEST FOR ADDITIONAL INFORMATION FROM FTC UNDER HART-SCOTT-RODINO ACT AND ANNOUNCE EXTENSION OF TENDER OFFER FOR SHARES OF SPARK THERAPEUTICS, INC.

Jun 10 2019

Deals of the day-Mergers and acquisitions

May 14 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

May 14 2019

Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

Apr 15 2019

UPDATE 3-Catalent seeks slice of gene therapy market with Paragon buy

April 15 Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

Apr 15 2019

Catalent to buy Paragon Bioservices for $1.2 billion: WSJ

Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

Apr 14 2019

UPDATE 1-Catalent to buy Paragon Bioservices for $1.2 bln -WSJ

April 14 Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

Apr 14 2019

Biogen to buy Nightstar Therapeutics in $800 mln cash deal

Biogen Inc said on Monday it will buy Nightstar Therapeutics Plc for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market.

Mar 04 2019

UPDATE 2-Biogen to buy Nightstar Therapeutics in $800 mln cash deal

March 4 Biogen Inc said on Monday it will buy Nightstar Therapeutics Plc for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market.

Mar 04 2019

BRIEF-Spark Therapeutics Says Upon Termination Of Deal with Roche, Under Specified Circumstances, Co Will Be Required To Pay To Roche A Termination Fee Of $144 Mln

* SPARK THERAPEUTICS - UPON TERMINATION OF DEAL, UNDER SPECIFIED CIRCUMSTANCES, CO WILL BE REQUIRED TO PAY TO ROCHE A TERMINATION FEE OF $144 MILLION. Source text: (https://bit.ly/2TfvJRj) Further company coverage:

Feb 25 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates